I suspect these words are purposeful.  Given many other Canadien bios have consolidated, moved to the NASDAQ and are financing at $5, $9 and even $46 USD ( see David's "mother of all bios" ) I suspsect our 60 or 70 cent CAD financing will be anything but public and clearly the intended ( strategic investment partners ) are already firmly in the que.  The escort service that has arrived on the bullboard to assist in the selling of the concept is no surprise.  Nice to see the dip to .54 CAD and the discussion around years of required development...oh indeed..tell us just how bad this most advanced company is...

Last year the insiders took their options in June.  Typically they take them in late January, this year they postponed the doling out of options until Feb.26/20 and did so after we plunged to .58 on Feb.25/20.  The options were taken at .63.  Some are suggesting they were squeezed in now because in June our share price will have appreciated to levels where it "should be".  The expectation now is that the 10M ( likely closer to 12 or 13M when done ) will find it's way to the US as we prime the pump and finally show ourselves in the market that will ultimately make the company. Given the fact we are waiting on a FDA approval ( submitted Oct.25/19 ) for our DIMI home dialysis pump, running a confirmatory phase 3B TIGRIS trial ( remember we achieved FDA Compassionate Care in our initial phase III effort AND are using 179 patients data as part of the phase 3B TIGRIS ), have a partnership with Baxter ( 5M upfront was a WIN / WIN ...looks weak for EDT and cheap look for Baxter - tho I suspect their "look" is far more focussed than many realize ), have had about $800K CAD land in the kitty from recent option / warrant exercising and now have growing revenues and very little burn....it is a curious bit of activity that falls directly in-line with the last 19 years of advancement.  Once the the financing is complete we will have about 20M CAD in the kitty and NO debt.  We will get a repsonse from the FDA on DIMI home dialysis pump ( remember SAMI, DIMI's twin brother is already FDA approved ) and we will close in on transparent NR's surrounding our 150 person phase 3B confirmatory trial with partner Baxter.  I suspect the deal needed to be sweet for those in charge of pushing the GO button, 10M is chump change for the BIG-Boys, they'll likely want more and "more" will make the SP move ( there is NO traffic here, most tightly held 200M + stock on the TSX as determined by the STIG ( Southern Tier Investment Group ) ALL in MY Humble Opinion!  Stay in school! 

I expect there to be some buying from people they might not want to buy, but people educated enough to recognize the the value in this play.  Many Canadien bios are financing and SELLING to the public...this story the opposite....SELLING weakness and providing opportunities to those that are in charge of introducing this most advanced / modest little "start-up" from Canada.  We thank Natalie our official beat ( down ) reporter that described us as a "small Canadien drug-maker" and acted as our web-site welcome mat..in the same general position as the wolfhound doggy-style tale.....tough to take this man-made drama from these fare-y tale artists, but indeed worth wading thru the overburden as the content is rather $tunning...just not even close to being placed in full view.  Does make you wonder just what the 5 cent , 4 cent and eventually 3 cent and under review targets from the 2 former analysts were really all about..were they real?  They did finance this at 70 cents CAD to the tune of $12M CAD.  Nothing worse than an over-seasoned bowl of BS soup....I'm quite confident unsuspecting EDT non-insiders have been fed a steady diet of this broth for a very long time..now is the time to take cheap paper away from the chef$...they own it all and seem ready to ensure that they give up little...stay tuned

Down with the flu...I will be posting all day as I am boared ; - )

Tommy
PS= CTSO just announced a net loss of 19.3M USD ( more than 25M CAD ) they have been raising money ATM ( at the market ( ~ $6.share USD ) to the tune of 13M USD and are now mostly focussed on Corona whilst their FDA trial ( little to do with Sepsis ) remains suspended.....Hmmmmm? which company to buy? ; - )